Fig. 2From: Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patientsDisplays the four direct cost categories in relation to the total amount of direct costs. Patients with Alpha-1-antitrypsin deficiency (AATD) and augmentation therapy (AT) have lower inpatient but also higher outpatient costs, compared to the two other subgroups. Therefore, no significant differences could be detected between the three groups. However, AATD patients - especially non AT receiving AATD patients - tended to have lower direct costsBack to article page